Shares of Hims & Hers Health Inc. (HIMS) surged 5.11% in Monday's pre-market session, following positive analyst coverage and raised price targets from Piper Sandler.
Analysts at Piper Sandler maintained a "Hold" rating on Hims & Hers Health but raised their price target on the stock from $21 to $24, reflecting potential growth opportunities for the company in the beauty and wellness sector.
While the firm highlighted interest rates, lending standards, and potential policies from the incoming administration as key factors to watch, it expressed optimism for U.S. beauty and wellness companies in 2025, positioning Hims & Hers Health as one of its top ideas for the year.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。